| 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy (NCT02243176) | AstraZeneca | 2014-09-01 |
| Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes (NCT02158741) | McMaster University | 2014-09-01 |
| COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes (NCT02863523) | East Carolina University | 2014-09-01 |
| Transformation of Indigenous Primary Healthcare Delivery (NCT02234973) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-09-01 |
| Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics (NCT02377076) | Federal University of Vicosa | 2014-09-01 |
| Forxiga Tablets Specific Clinical Experience Investigation for Elderly (NCT02200627) | AstraZeneca | 2014-09-01 |
| Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State (NCT02223065) | AstraZeneca | 2014-09-01 |
| Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus. (NCT02206607) | Pfizer | 2014-09-01 |
| Dietary Intervention Modifies Gut Microbiota in Type 2 Diabetes. (NCT03421301) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2014-08-07 |
| Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine (NCT02200991) | Sanofi | 2014-08-01 |
| A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage (NCT02214654) | Tianjin Medical University | 2014-08-01 |
| Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes (NCT02220907) | Tanabe Pharma Corporation | 2014-08-01 |
| Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus (NCT02185482) | Adwin Life Care | 2014-08-01 |
| Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes (NCT02185755) | Endocrine Research Society | 2014-08-01 |
| Diabetes Lifestyle Assessment and Educational Tools (NCT01858506) | Ofra Kalter-Leibovici MD | 2014-08-01 |
| Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus (NCT02227849) | Tanabe Pharma Corporation | 2014-08-01 |
| Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (NCT02220920) | Tanabe Pharma Corporation | 2014-08-01 |
| A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes (NCT02227303) | Medidata Solutions | 2014-08-01 |
| RCT Evaluating Effects of Cosmos Caudatus (Ulam Raja) in T2DM Patients (NCT02322268) | Universiti Putra Malaysia | 2014-08-01 |
| Lung Function in Patients With Early Type 2 Diabetes Mellitus (NCT03167918) | Liaoning University of Traditional Chinese Medicine | 2014-07-21 |
| Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients (NCT02151461) | NuSirt Biopharma | 2014-07-01 |
| Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes (NCT02222350) | Daiichi Sankyo Co., Ltd. | 2014-07-01 |
| Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose (NCT02727790) | Assaf-Harofeh Medical Center | 2014-07-01 |
| Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia (NCT02186080) | Seoul National University Hospital | 2014-07-01 |
| Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus (NCT02123732) | Laniado Hospital | 2014-07-01 |
| Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)" (NCT02221284) | Takeda | 2014-06-30 |
| Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. (NCT02157298) | AstraZeneca | 2014-06-01 |
| TOFO Insulin Combination Trial (NCT02201004) | Sanofi | 2014-06-01 |
| Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes (NCT02089126) | LG Life Sciences | 2014-06-01 |
| A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes (NCT02198846) | Konkuk University Medical Center | 2014-06-01 |
| Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment (NCT02132338) | Federal University of Minas Gerais | 2014-06-01 |
| Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients (NCT02346175) | Jiangsu HengRui Medicine Co., Ltd. | 2014-06-01 |
| A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus (NCT02158078) | CeQur Corporation | 2014-06-01 |
| Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure (NCT02130687) | Vanderbilt University | 2014-06-01 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes (NCT02148861) | Novo Nordisk A/S | 2014-05-26 |
| Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes (NCT02049814) | Takeda | 2014-05-09 |
| Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control (NCT02104804) | AstraZeneca | 2014-05-07 |
| Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 (NCT02212951) | Biodel | 2014-05-01 |
| A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes (NCT02132637) | Eli Lilly and Company | 2014-05-01 |
| Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin (NCT02135549) | Boston Therapeutics | 2014-05-01 |
| Can Vitamin D Supplementation Prevent Type 2 Diabetes? (NCT02112721) | Monash University | 2014-05-01 |
| Diabetes-Specific Nutritional Formulas Versus Oatmeal (NCT02691481) | Joslin Diabetes Center | 2014-05-01 |
| Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis (NCT02172716) | University of Sao Paulo | 2014-05-01 |
| OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus (NCT02054650) | University of North Texas Health Science Center | 2014-05-01 |
| Diabetes Effects on Long-Term Implant Survival and Success (NCT02282046) | The University of Texas Health Science Center at San Antonio | 2014-05-01 |
| Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) (NCT02099110) | Merck Sharp & Dohme LLC | 2014-04-22 |
| A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea (NCT04980040) | Takeda | 2014-04-19 |
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. (NCT01991197) | University College Dublin | 2014-04-01 |
| Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus (NCT02093702) | Royal Victoria Hospital, Canada | 2014-04-01 |
| A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus (NCT02175784) | Astellas Pharma Inc | 2014-03-31 |
| Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD (NCT03392961) | Biocon Limited | 2014-03-27 |
| Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients (NCT02477865) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2014-03-23 |
| Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) (NCT02036515) | Merck Sharp & Dohme LLC | 2014-03-12 |
| Incretin-based Drugs and the Risk of Heart Failure (NCT02456428) | Canadian Network for Observational Drug Effect Studies, CNODES | 2014-03-01 |
| Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus (NCT02169531) | B & Y Technologies | 2014-03-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes (NCT02077452) | Hua Medicine Limited | 2014-03-01 |
| The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes (NCT02248714) | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 2014-03-01 |
| A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus (NCT02091362) | Eli Lilly and Company | 2014-03-01 |
| A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin (NCT02053116) | Pfizer | 2014-03-01 |
| Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes (NCT02687152) | Karolinska Institutet | 2014-03-01 |
| An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes (NCT02082184) | Abbott Diabetes Care | 2014-03-01 |
| Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (NCT02015299) | dr. DJ Mulder | 2014-03-01 |
| A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin (NCT02053103) | Pfizer | 2014-03-01 |
| Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (NCT02477969) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2014-02-27 |
| The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) (NCT02059187) | Merck Sharp & Dohme LLC | 2014-02-11 |
| Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide) (NCT04349696) | Orient Europharma Co., Ltd. | 2014-02-11 |
| Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC) (NCT02060201) | AstraZeneca | 2014-02-01 |
| Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance (NCT02109094) | Yale University | 2014-02-01 |
| Inulin,SCFA Production and Metabolic Response (NCT02009670) | Maastricht University Medical Center | 2014-02-01 |
| Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy (NCT02068443) | Takeda | 2014-02-01 |
| Diabetes Coaching Study (NCT02066831) | West German Center of Diabetes and Health | 2014-02-01 |
| Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals (NCT02031341) | Amsterdam UMC, location VUmc | 2014-01-01 |
| The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes (NCT02311244) | University of Roma La Sapienza | 2014-01-01 |
| Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes (NCT02081599) | Tanabe Pharma Corporation | 2014-01-01 |
| Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients (NCT02235519) | Hospital General de México Dr. Eduardo Liceaga | 2014-01-01 |
| Pre-meal Protein Drink Improve Glycemic Regulation (NCT01987674) | Lund University | 2014-01-01 |
| Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (NCT01999218) | Merck Sharp & Dohme LLC | 2013-12-16 |
| A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (NCT02033889) | Merck Sharp & Dohme LLC | 2013-12-13 |
| A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001) (NCT01986855) | Merck Sharp & Dohme LLC | 2013-12-02 |
| A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus (NCT02853630) | India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals | 2013-12-01 |
| Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes (NCT01654341) | Hospital Universitario Getafe | 2013-12-01 |
| Drug-drug Interaction Study(Lobeglitazone, Warfarin) (NCT02002611) | Chong Kun Dang Pharmaceutical | 2013-12-01 |
| Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis (NCT02015780) | Takeda | 2013-12-01 |
| Glargine Versus NPH in Patients With Chronic Kidney Disease (NCT02451917) | University of Sao Paulo General Hospital | 2013-12-01 |
| A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes (NCT02020616) | Eli Lilly and Company | 2013-12-01 |
| Patient-Centered Smartphone-Based Diabetes Care (NCT02313363) | Seoul National University Hospital | 2013-12-01 |
| Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (NCT02540486) | LMC Diabetes & Endocrinology Ltd. | 2013-12-01 |
| Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus (NCT02097342) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2013-12-01 |
| Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion (NCT02010827) | University Hospital, Gentofte, Copenhagen | 2013-11-01 |
| Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes (NCT01960179) | Sanofi | 2013-11-01 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (NCT01919684) | Ligand Pharmaceuticals | 2013-11-01 |
| Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus (NCT02680457) | University of Guadalajara | 2013-11-01 |
| Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003) (NCT01971554) | Merck Sharp & Dohme LLC | 2013-10-14 |
| A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO) (NCT01958671) | Merck Sharp & Dohme LLC | 2013-10-09 |
| Safety Evaluation of Adverse Reactions in Diabetes (NCT02092597) | Charles University, Czech Republic | 2013-10-01 |
| Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients (NCT02026024) | Chang Gung Memorial Hospital | 2013-10-01 |
| Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes (NCT01933672) | Pfizer | 2013-10-01 |
| Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients (NCT02244879) | University of Turin, Italy | 2013-10-01 |
| Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes (NCT01968265) | Ionis Pharmaceuticals, Inc. | 2013-10-01 |
| A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test (NCT01936025) | Profil Institut für Stoffwechselforschung GmbH | 2013-10-01 |